[Hereditary hemochromatosis].
Genetic hemochromatosis is classified into four subtypes of which only type 1 is of clinical importance in Caucasians. Type 1 is due to an autosomal recessive inborn error of metabolism; the homozygous C282Y mutation of the HFE gene on chromosome 6 accounts for more than 90% of the clinical phenotype in populations of Celtic origin. The mutation leads to an inadequately high intestinal iron absorption which may finally cause iron overload in and damage to various organs. Type 2 is the juvenile form of iron overload which leads to a severe phenotype prior to age 30 with cardiomyopathy and hypogonadism. The corresponding mutations are located in the hemojuveline and hepcidin genes. Typ 3 has mainly been described in Italian families and refers to mutations in transferrin receptor 2 gene. Histopathologic and clinical consequences of type 3 hemochromatosis are similar to those seen in type 1. Types 2 and 3 are autosomal recessive traits. Type 4 hemochromatosis follows an autosomal dominant trait; the corresponding mutation affects the basolateral iron carrier ferroportin 1. Diagnosis of hemochromatosis is based on determinations of serum ferritin and transferrin saturation with the latter being more sensitive and specific. In case of a homozygous C282Y gene test, liver biopsy is not required for diagnosis. Liver biopsy is, however, recommended in C282Y homozygotes at ferritin values > 1,000 ng/ml because of an increased risk for liver fibrosis. Phlebotomy treatment is the standard care to remove iron in genetic hemochromatosis. Patients treated in the early noncirrhotic stage have a normal life expectancy. Thus, future efforts should aim at early diagnosis. Iron removal also improves the outcome in cirrhotic patients. Liver carcinoma may develop in cirrhotic patients despite iron depletion. Liver cancers without cirrhosis are so rare that screening is only recommended in cirrhotic patients.
Niederau
Claus
C
Katholische Kliniken Oberhausen gGmbH, St Josef-Hospital, Klinik für Innere Medizin, Akademisches Lehrkrankenhaus der Universität Duisburg-Essen, Duisburg-Essen. claus.niederau@st-josef.de
D000328:Adult; D000483:Alleles; D001706:Biopsy; D001815:Bloodletting; D009202:Cardiomyopathies / Q000235:genetics; D027682:Cation Transport Proteins / Q000235:genetics; D002614:Chelating Agents / Q000627:therapeutic use; D002869:Chromosome Aberrations; D002889:Chromosomes, Human, Pair 2 / Q000235:genetics; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics; D004252:DNA Mutational Analysis; D042241:Early Diagnosis; D005799:Genes, Dominant / Q000235:genetics; D005808:Genes, Recessive; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006432:Hemochromatosis / Q000145:classification / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D006720:Homozygote; D006801:Humans; D007006:Hypogonadism / Q000235:genetics; D007501:Iron / Q000097:blood; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000235:genetics; D008565:Membrane Proteins / Q000235:genetics; D026901:Membrane Transport Proteins / Q000235:genetics; D019683:Penetrance; D010641:Phenotype; D017354:Point Mutation / Q000235:genetics; D011379:Prognosis; D058979:Proton-Coupled Folate Transporter; D011990:Receptors, Transferrin / Q000235:genetics; D000098742:Ferroportin; D000099236:Solute Carrier Family 11, Member 2
D027682:Cation Transport Proteins; D002614:Chelating Agents; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D007501:Iron; D008565:Membrane Proteins; D026901:Membrane Transport Proteins; D058979:Proton-Coupled Folate Transporter; D011990:Receptors, Transferrin; D000098742:Ferroportin; D000099236:Solute Carrier Family 11, Member 2; C103673:HFE protein, human; C505058:SLC46A1 protein, human; C503640:TFR2 protein, human